ReviewPharmaceutics2020
Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- Solubility-Enhanced α‑Mangostin Bilayer Films: Synergizing Mucoadhesion and Protection for Effective Aphthous Ulcer Treatment.ACS omega · 2026Article
- From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics.Materials today. Bio · 2025Review
- Article
- Oil-in-water nanoemulsions for glaucoma treatment: An insight into the latest trends.BioImpacts : BI · 2025Review
- Development and Evaluation of Different Electrospun Cysteamine-Loaded Nanofibrous Webs: A Promising Option for Treating a Rare Lysosomal Storage Disorder.Pharmaceutics · 2024Article
- Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy.International journal of pharmaceutics: X · 2024Article
- Application of iontophoresis in ophthalmic practice: an innovative strategy to deliver drugs into the eye.Drug delivery · 2023Review
- Article
- Polymer-Based Self-Assembled Drug Delivery Systems for Glaucoma Treatment: Design Strategies and Recent Advances.Polymers · 2023Review
- Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma, review and update.Journal of nanobiotechnology · 2023Review
- Nano-Based Drug Delivery Systems for Periodontal Tissue Regeneration.Pharmaceutics · 2022Review
- Recent Advances in Ophthalmic Drug Delivery.Pharmaceutics · 2022Article
- Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update.Nutrients · 2022Review
- Critical Evaluation of Multifunctional Betaxolol Hydrochloride Nanoformulations for Effective Sustained Intraocular Pressure Reduction.International journal of nanomedicine · 2022Article
- Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts.Pharmaceutics · 2021Review
- 3D Printing-A "Touch-Button" Approach to Manufacture Microneedles for Transdermal Drug Delivery.Pharmaceutics · 2021Review
- pHEMA: An Overview for Biomedical Applications.International journal of molecular sciences · 2021Review
- Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients' non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.